Real-World Experience of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Predictors for Improvement in Patient-Reported Outcomes in Complement Inhibitor–Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Eculizumab and Ravulizumab
- Development of a Target Concentration Intervention to Individualize Paroxysmal Nocturnal Hemoglobinuria Treatment With Pegcetacoplan
Disclosure statements are available on the authors' profiles:
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
Am. J. Hematol 2024 May 01;99(5)816-823, M Griffin, R Kelly, I Brindel, L Maafa, R Trikha, P Muus, T Munir, AM Varghese, L Mitchell, S Nagumantry, S Gandhi, A Pike, AG Kulasekararaj, R Peffault de LatourFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.